Quick View: Merck Re-Enters Ophthalmology With EyeBio Acquisition, Advancing Keytruda Diversification Strategy
Pharmaceuticals / United States / Mon 03 Jun, 2024
The Latest: On May 29 2024, Merck announced the acquisition of EyeBio, a clinical-stage biotechnology company specialising in ophthalmology drug development. Under the terms of the agreement, Merck will pay US1.3bn upfront and another US1.7bn contingent on achieving certain development, regulatory and commercial milestones